When individuals were presented with risk and benefit information about statins, they required 50-75% relative reduction in risk in order to find taking a statin acceptable. Statins provide a 25% ...
NEW ORLEANS — The first global randomized trial of the PCSK9 inhibitor evolocumab for the prevention of a primary major adverse cardiovascular event (MACE) found a relative reduction in risk similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results